SEC Comment Letter for Compass Therapeutics, (CMPX) — Jan 2, 2026
Compass Therapeutics, Inc.
Date: Jan. 2, 2026 · CIK: 0001738021 · Accession: 0000000000-26-000023
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292491
Letter
Re: Compass Therapeutics, Inc. Registration Statement on Form S-3 Filed December 30, 2025 File No. 333-292491 Dear Barry Shin:
January 2, 2026
Barry Shin Chief Financial Officer Compass Therapeutics, Inc. 80 Guest Street Suite 601 Boston, Massachusetts 02135
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Finnbarr Murphy, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 2, 2026 Barry Shin Chief Financial Officer Compass Therapeutics, Inc. 80 Guest Street Suite 601 Boston, Massachusetts 02135 Re: Compass Therapeutics, Inc. Registration Statement on Form S-3 Filed December 30, 2025 File No. 333-292491 Dear Barry Shin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finnbarr Murphy, Esq. </TEXT> </DOCUMENT>